Recombinant Anti-Tyrosyl tRNA synthetase/TyrRS antibody [EPR9927] (ab154819)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9927] to Tyrosyl tRNA synthetase/TyrRS
- Suitable for: WB, ICC/IF
- Reacts with: Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Tyrosyl tRNA synthetase/TyrRS antibody [EPR9927]
See all Tyrosyl tRNA synthetase/TyrRS primary antibodies -
Description
Rabbit monoclonal [EPR9927] to Tyrosyl tRNA synthetase/TyrRS -
Host species
Rabbit -
Tested applications
Suitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP -
Species reactivity
Reacts with: Rat, Human
Predicted to work with: Mouse -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- C6; PC12; Raji; HeLa and ECV 304 cell lysates; HeLa cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20ºC. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR9927 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab154819 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 59 kDa.
|
|
ICC/IF |
1/250 - 1/500.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 59 kDa. |
ICC/IF
1/250 - 1/500. |
Target
-
Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr). -
Involvement in disease
Defects in YARS are the cause of Charcot-Marie-Tooth disease dominant intermediate type C (CMTDIC) [MIM:608323]. CMTDIC is a form of Charcot-Marie-Tooth disease characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. -
Sequence similarities
Belongs to the class-I aminoacyl-tRNA synthetase family.
Contains 1 tRNA-binding domain. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 8565 Human
- Entrez Gene: 107271 Mouse
- Entrez Gene: 313047 Rat
- Omim: 603623 Human
- SwissProt: P54577 Human
- SwissProt: Q91WQ3 Mouse
- SwissProt: Q4KM49 Rat
- Unigene: 213264 Human
see all -
Alternative names
- CMTDIC antibody
- SYYC_HUMAN antibody
- Tyrosine tRNA ligase, cytoplasmic antibody
see all
Images
-
All lanes : Anti-Tyrosyl tRNA synthetase/TyrRS antibody [EPR9927] (ab154819) at 1/1000 dilution
Lane 1 : C6 cell lysate
Lane 2 : PC12 cell lysate
Lane 3 : Raji cell lysate
Lane 4 : HeLa cell lysate
Lane 5 : ECV-304 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 59 kDa -
Immunofluorescence analysis of HeLa cells, labeling Tyrosyl tRNA synthetase / TyrRS using ab154819 at 1/250 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab154819 has been referenced in 3 publications.
- Zhang C et al. YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling. J Cancer Res Clin Oncol 146:329-342 (2020). PubMed: 31912229
- Shorrock HK et al. UBA1/GARS-dependent pathways drive sensory-motor connectivity defects in spinal muscular atrophy. Brain 141:2878-2894 (2018). PubMed: 30239612
- Pease-Raissi SE et al. Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration. Neuron 96:373-386.e6 (2017). PubMed: 29024661